Abstract

Purpose To search for the utility of DCE-MRP to differentiate between posttreatment enhancement (PT) and tumoral enhancement (TM) in high-grade glial tumors. Materials and Methods Thirty-four patients with glioma (11 grade 3; 23 grade 4) were enrolled. Enhancement in the vicinity of the resection cavity demonstrated by DCE-MRP was taken into consideration. Based on the follow-up scans, reoperation or biopsy results, the enhancement type was categorized as PT or TM. Measurements were performed at the enhancing area near the resection cavity (ERC), nearby (NNA) and contralateral nonenhancing areas (CLNA). Perfusion parameters of the ERC were also subtracted from NNA and CLNA. Intragroup comparison (paired sample t-test) and intergroup comparison (Student's t-test) were made. Results There were 7 PTs and 27 TMs. In the PT, the subtracted values of Ve and IAUC from the CLNA and NNA and the subtracted value of Kep from NNA were statistically different. In TM, all metrics were significantly different comparing the CLNA and NNA. Comparing PT with TM, Ktrans, IAUC, Kep, and subtracted values of Ktrans and IAUC from both NNA and CLNA were significantly different. Conclusions In PT, only Ktrans values did not reveal any difference comparing NNA and CLNA. To differentiate PT from TM, Ktrans, Kep, IAUC, and subtracted values of Ktrans and IAUC from NNA and CLNA can be used. These findings are in concordance with literature.

Highlights

  • High-grade gliomas are aggressive primary brain tumors characterized by high cellularity, anaplasia, mitosis, additional microvascular proliferation, and necrosis [1, 2]

  • Comparing the ERC with the CLNA and NNA, Ve and IAUC were found to be statistically different within group evaluation

Read more

Summary

Introduction

High-grade gliomas are aggressive primary brain tumors characterized by high cellularity, anaplasia, mitosis (grade 3), additional microvascular proliferation, and necrosis (grade 4) [1, 2]. Postsurgical diffusion restriction at the periphery of the resection cavity in the acute period continues to enhance in the subacute period following 2–3 months after operation. It is not Contrast Media & Molecular Imaging easy to distinguish between posttreatment enhancement (PT) and tumoral enhancement (TM) by conventional contrastenhanced brain MRI. This distinction is essential as it affects follow-up time interval and treatment protocol. Any failure in the evaluation may lead to unnecessary reoperations or premature termination of chemotherapy [8,9,10]

Objectives
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call